Save
Comparing the effect of glatiramer acetate 20 mg vs glatiramer acetate 40 mg on retinal structures in patients with relapsing remitting multiple sclerosis
Author(s): ,
M. Gilroy
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
R. Darling
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
S. Lichtman-Mikol
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
S. Razmjou
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
E. Probst-Simmons
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
,
C. Santiago-Martinez
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
E. Bernitsas
Affiliations:
Neurology, Wayne State University - School of Medicine, Detroit, MI, United States
ECTRIMS Online Library. Santiago-Martinez C.
Oct 12, 2018; 228996
Carla Santiago-Martinez
Carla Santiago-Martinez
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1156

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - OCT

Objective: To compare the effect of glatiramer acetate 20 mg (GA20) daily injection vs glatiramer acetate 40 mg (GA40) three times a week on retinal structures in patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Background: The efficacy and safety of glatiramer acetate subcutaneous injections has been well established in MS patients. GA40 injection is administered three times a week and is more favorable over GA20 daily injections. As retinal thickness decreases in MS patients over time, it is important to compare the effect of each treatment on retinal structures.
Design/Methods: 29 RRMS patients on GA20 mg daily injections (23 women, 6 men) and 18 RRMS patients on GA40 mg injections three times a week (12 women, 6 men) were included in this cross-sectional analysis. The mean age ±SD were 48.3 ±7.4 and 43.8 ±8.8 for GA20 and GA40, respectively. Optical coherence tomography (OCT) was performed by an experienced technician to quantify the papillomacular bundle (PMB) and the peripapillary retinal nerve fiber layer (pRNFL) quadrant thicknesses: superior, inferior, temporal, nasal. Intra-retinal segmentation was performed to obtain total macular volume (TMV), retinal nerve fiber (RNFL), ganglion cell (GCL), inner plexiform (IPL), inner nuclear (INL), outer plexiform (OPL) and outer nuclear (ONL) layer thickness.​ A generalized linear model with OCT parameters as dependent variables and treatment groups as independent variable was used to analyze our data. Age, disease duration, sex and race were all included as covariates. (SPSS vs 24).
Results: There was no significant difference in retinal thickness between GA20 and GA40. The mean global pRNFL thickness was 91.6 ±12.9 and 95.2 ±11.8 in GA20 and GA40, respectively (p=0.48). The mean RNFL thickness was 0.79 ±0.13 in patients on GA20 and 0.82 ±0.12 in the GA40 group without a significant group difference (p=0.51).
Conclusion: Our study demonstrates similar effectiveness of GA20 and GA40 on retinal structures in RRMS patients. Because GA40 is a three times/week injection as opposed to GA20 daily injections, GA40 is a favorable, more convenient treatment option for RRMS patients.
Disclosure: Evanthia Bernitsas: DMC Foundation, Roche/Genetech, Sanofi/Genzyme, Biogen, Novartis, Chugai, Medimmune, EMD Serono. Melody Gilroy, Rachel Darling, Sara Razmjou, Samuel Lichtman-Mikol, Ellyse Probst-Simmons and Carla Santiago-Martinez: All have nothing to disclose.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings